Medicare AdvantageCoverageMedium impact
MA06.006h, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross·Infectious Disease, Family Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.006h for Lyme Disease diagnosis and IV antibiotic therapy has been updated. This affects coverage and potentially prior authorization requirements for Lyme disease treatment including intravenous antibiotics.
Action Required
Before April 1, 2026: Billing team must review updated MA06.006h policy for Lyme disease diagnosis and IV antibiotic therapy coverage criteria. Update prior authorization workflows and provider documentation requirements for Medicare Advantage Lyme disease cases. Verify coverage guidelines in billing system to prevent claim denials.